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Abstract
DTI -015 (BCNU in 100% ethanol ) utilizes solvent
facilitated perfusion for the intratumoral treatment of
gliomas. The ethanol solvent vehicle facilitates a rapid
and thorough saturation of the tumor with the dissolved
anticancer agent BCNU. We conducted a phase I / II dose
escalation study of DTI-015 in 40 heavily pretreated
patients with inoperable recurrent malignant glioma.
The study goals were to establish a maximally tolerated
dose (MTD) for DTI-015 and assess its safety and
activity. Patients received stereotactic intratumoral
injection of DTI-015 under magnetic resonance imaging
guidance. Dose escalation was performed in two
phases. First, DTI-015 volume was escalated at a set
BCNU concentration of 12.5 mg/ml; second, BCNU mg
dose was escalated by increasing BCNU concentration
to 30, 45, 60, and 75 mg/ml. A MTD of 5 ml and 240 mg
was established. Twenty-five of 28 DTI-015 treatments
(89%) using MTD were administered safely without
producing high-grade drug-related adverse events. Me-
dian survival for GBM patients administered DTI-015 at
MTD was 55 weeks. Magnetic resonance imaging de-
monstrated stable disease in 72% of evaluable patients
with a median of 10.5 weeks. The results suggest that
DTI-015 administered at MTD is well tolerated and
active in patients with inoperable recurrent GBM.
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Introduction
Approximately 14,000 new cases of malignant glioma are
diagnosed each year in the US [16]. Despite a multimodality
approach using surgery, radiotherapy and chemotherapy, the
prognosis is poor, with a median survival of approximately 1
year following diagnosis for patients with glioblastoma
multiforme. Effective drug treatments for malignant gliomas
have proven elusive, due in part, to the presence of the blood
brain barrier. A number of approaches have been used in an
attempt to overcome this obstacle to drug delivery in the
brain. High-dose intravenous delivery of chemotherapeutic
agents has been attempted but is limited by systemic toxicity.
BCNU has been delivered using intraarterial administration in
an attempt to increase tumor dosing. This, however, results
in extensive neurological toxicity, and provides no increase in
survival compared to intravenous BCNU [4,8,13].
Using local delivery of antitumor agents, through the
interstitial space, investigators have sought to bypass the
blood brain barrier, thereby increasing amounts of anticancer
drugs that can be delivered to the tumor. Gliadel1 incorpo-
rates BCNU in a solid polymer wafer depot, and in clinical
studies demonstrated a small but significant benefit in com-
bination with surgery in patients with recurrent gliomas [3].
Gliadel1 and other depot approaches, however, deliver the
drug through the interstitial space by diffusion, which limits
tissue penetration to a few millimeters.
To extend the penetration distance of anticancer drugs in
brain tumors, Bobo et al. [1 ], Laske et al. [6 ], and Morrison
et al. [9 ] developed convection enhanced delivery (CED),
which uses pressurized interstitial injection of anticancer
agents in aqueous fluids delivered at low flow rates. In
preclinical testing, this approach has been demonstrated to
produce large distribution volumes [1,5,7]. Our research with
DTI-015 (a combination of BCNU in ethanol ) suggests that
drug delivery through the intratumoral route may be
accomplished effectively by solvent facilitated perfusion,
which utilizes water -miscible organic solvent delivery ve-
hicles, rather than the aqueous vehicles used in convection
enhanced delivery. We have hypothesized that the dual
properties of the solvent, of water miscibility and membrane
permeability, facilitate a rapid and thorough penetration of
high concentrations of the anticancer agent solute throughout
solid tumors following intratumoral injection [11,12,14].
Based upon the efficacy demonstrated in tumor models
[10,11,14], a phase I / II trial was conducted to study the
safety and activity of DTI-015 in patients with inoperable
recurrent malignant glioma.
Patients and Methods
Clinical Study Protocol
Clinical study Protocol ID 95-115 was conducted under
physician-sponsored IND #48,726 using DTI-015 in patients
Neoplasia . Vol. 5, No. 1, January 2003, pp. 9 – 16
www.neoplasia.com
9
Address all correspondence to: Dennis Pietronigro, PhD, Direct Therapeutics, Inc., 6
Emerson Court, Katonah, NY 10536, USA. E -mail: dpietronigro@directtherapeutics.com
Received 13 August 2002; Accepted 27 September 2002.
Copyright# 2003 Neoplasia Press, Inc. All rights reserved 1522-8002/03/$25.00
RESEARCH ARTICLE
with inoperable recurrent malignant gliomas. The study pro-
tocol was approved by the Institutional Review Boards
( IRBs) of the MD Anderson Cancer Center (MDACC) in
Houston and the Cleveland Clinic and initiated in December
1995. Patients gave informed consent before entering the
study. Described here are the results as of October 24, 2001.
Patient Selection
The protocol required patients between 18 and 75 years
of age with histologic proof of recurrent, previously irradiated
supratentorial glioblastoma multiforme, anaplastic astrocy-
toma, anaplastic oligodendroglioma, or anaplastic ependy-
moma. It must have been judged that gross total resection of
the patient’s tumor was not possible or the patient had
refused to have a resection of the tumor. Patients must have
had a Karnofsky performance score (KPS) rating 60, with
an inoperable recurrent tumor volume of 0.5 and 13 cm3
and undergoing a stereotactic biopsy or open craniotomy for
clinical reasons other than injection of DTI-015. Patients
must have been fully recovered from the acute effects of any
prior chemotherapy or radiotherapy. For females of child -
bearing potential, the patient must not have been pregnant
as evidenced by a menstruation in the last 8 weeks or by a
negative urine human chorionic gonadotropin (HCG) preg-
nancy test.
The exclusion criteria excluded patients receiving any
radiotherapy or chemotherapy during 4 weeks before enter-
ing the study or any treatment with nitrosoureas or mitomycin
during 6 weeks before entering the study, patients with active
uncontrolled infection, serious liver or bone marrow disorder,
evidence of renal failure, bleeding diathesis, and patients
using anticoagulant medication. Ovoid or spherical tumors
were allowed as were tumors with central necrosis or cystic
areas as long as an enhancing rim of thickness 5 mm was
present.
Patient Evaluation and Management
Each patient underwent a thorough medical examination
before intratumoral injection of DTI-015. These included
medical history, physical examination, KPS determina-
tion, neurological examination, mini -mental state examina-
tion, tumor imaging by magnetic resonance imaging (MRI)
scans, and laboratory examinations. Starting the day before
injection, the patients’ steroid dose was set to 10 mg
intravenous or oral every 6 hours or the dose of the previous
day whichever was larger and also loaded andmaintained on
anticonvulsants preferably dilantin. Toxicity was assessed
by the use of NCI common toxicity grading criteria.
DTI-015 Injection and Tumor Volume Calculations
An MRI was performed before the injection of DTI-015.
The tumor volume was calculated using the three MRI slices
(one each in the coronal, sagittal, and axial view) having the
largest tumor area in that view. From the coronal slice, the
largest superior - inferior tumor diameter and the largest
lateral tumor diameter were determined. In the same way,
the largest superior - inferior tumor diameter and largest
anterior -posterior tumor diameter were measured from the
sagittal view, as were the largest anterior -posterior and
lateral diameters from the axial view. The two diameters for
each dimension were averaged to yield a lateral (dL),
anterior -posterior (dAP), and superior - inferior diameter
(dSI). Tumor volume was calculated as (4/3) p(dL/2)
(dAP/2)(dSI /2).
A twist drill was used to make a puncture in the scalp and
the skull, and the stereotactic needle was passed through the
dura to the center of the tumor. The malignant nature of the
tumor was confirmed by histological evaluation of frozen
sections from stereotactic biopsy material before injection of
DTI-015. The volume of DTI-015 injected was determined
as a percentage of tumor volume. DTI-015 (BCNU in
Table 1. Patient Characteristics.
Total patients 40
Male:Female 26:14
Caucasian 36
Hispanic 3
East Indian 1
Age median ( range ) 50 (23–73 ) years
Karnofsky median ( range ) 90 (50–100 )
Histology
Glioblastoma multiforme 26
Gliosarcoma 1
Anaplastic astrocytoma 9
Oligodendroglioma 2
Infiltrating astrocytoma 1
Mixed oligoastrocytoma 1
Tumor volume median ( range ) 6.1 ( 0.9–23.4 ) cm3
Table 2. DTI - 015 Treatment Regimens.
No. of patients /
No. of treatments
Dose
level
BCNU
concentration
(mg /ml )
DTI - 015
volume
(as percentage Tv )
Total
DTI - 015 volume
(ml )
Total BCNU
dose (mg )
4 / 5 I 12.5 25 0.6–2.0 7.5–25.0
5 /5 II 12.5 50 2.1–8.3 26.25–103.0
10 /13 III 12.5 75 0.7–10.5 8.75–131.25
5 /5 IV 30 50 0.4–5.0 13.2–150
1 /1 V 60 50 2.6 153
5 /5 VI 45 75 1.4–7.6 63–342
8 /8 VII 60 75 1.2–5.8 74–350
4 /4 VIII 75 75 2.7–4.9 203–369
Forty patients received 46 treatments. Two patients received treatment at two dose levels, one patient received treatment at dose levels II and III, and one patient
received treatment at dose levels VII and VIII. This accounts for the number of patients in column 1 totaling 42.
10 DTI -015 for Recurrent Glioma Hassenbusch et al.
Neoplasia . Vol. 5, No. 1, 2003
ethanol ) was supplied by Direct Therapeutics (Redwood
City, CA).
Multiple 1 ml syringes connected by means of a 10-cm IV
tubing to a Nashold reusable 5-mm window biopsy needle
were used to inject DTI-015 at the flow rates of 0.3 to 1.5 ml /
minute. Once the infusion was completed, the tubing was
clamped and the needle was left in place for 5 minutes. The
needle was removed and the scalp wound closed with a
single suture.
Dose Escalation and Maximally Tolerated Dose (MTD)
Preclinical studies of DTI-015 injection into normal rat and
feline brain demonstrated that both volume and milligram
dose (concentration) could contribute to the toxicity of DTI-
015 (unpublished results ). Therefore, dose escalation was
executed in two phases to distinguish the effects of these two
independent variables. In the first phase (dose levels I to III ),
volume was escalated using a set BCNU concentration of
12.5 mg/ml. Because the goal of intratumoral therapy is to
treat the tumor without causing damage to surrounding
normal brain, the absolute volume administered has to take
into account the tumor volume being injected. Consequently,
DTI-015 is administered as a percentage of the treated
tumor volume and volume escalation was accomplished by
increasing the volume of DTI-015 as a percentage of tumor
volume (25%, 50%, 75%). In the second phase (dose levels
IV to VIII ), BCNU milligram dose was escalated by in-
creasing BCNU concentration (30, 45, 60, and 75 mg/ml).
Escalation to the next higher dose was performed provided
at least three patients at each prior level showed no or
minimal toxicity (NCI toxicity grade 1 or 2). The MTD of DTI-
015 was determined by analyzing the frequency with which
high-grade drug-related adverse events (HGR-AEs) were
produced as a function of injection volume (ml), BCNU dose
(mg), BCNU concentration (mg/ml), injection volume per
tumor volume (ml /cm3 tumor), and BCNU dose per tumor
volume (mg/cm3 tumor).
Postinjection Follow-Up
Patients were followed for at least 2 days postoperatively
with particular attention to any adverse reaction to the
procedure or treatment. Vital signs, neurological examina-
tion, and all adverse events were closely followed and
recorded. Patients had monthly clinical follow-ups including
brain MRI scans. Disease progression was based on
changes in tumor volume using T1-weighted gadolinium
contrast enhancement according to classic NCI response
criteria.
Results
Patient Summary
Forty patients [26 male, 14 female between the ages of 23
and 73 years (median, 50) ] were enrolled in the study, 38 at
MDACC, and two at the Cleveland Clinic. Three patients
were Hispanic, one was East Indian, and the rest were
Caucasian. The histologic diagnosis was AA for 9 patients,
anaplastic oligodendroglioma for 2, GBM for 26, gliosarcoma
Table 3. Treatments Resulting in HGR-AEs and DTI -015 Dose Level
Cohorts.
Dose
level
Dosing HGR-AEs /
Total treatments
Percentage
HGR-AEs
I 12.5 / 25 1 / 5 20%
II 12.5 / 50 0 / 5 0%
III 12.5 / 75 4 / 13 31%
IV 30 /50 2 / 5 40%
V 60 /50 0 / 1 0%
VI 45 /75 2 / 5 40%
VII 60 /75 4 / 8 50%
VIII 75 / 75 2 / 4 50%
Figure 1. Bar chart showing DTI -015 injection volume (ml ) and patient number ordered by increasing injection volume. HGR-AEs are indicated by dark bars.
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for 1, infiltrating astrocytoma for 1, and mixed oligoastrocy-
toma for 1. The median KPS was 90 (range 50 to 100),
median age 50 (range 23 to 73), and median tumor volume
6.1 cm3 (range 0.9 to 23.4 cm3) (Table 1).
The study patients were extensively pretreated. Tumor
resections before the study were documented for all except
five patients and 14 of 40 (35%) patients had three or more
prior surgical procedures. All had previously been treated
with radiation, and 27 of 40 patients (68%) had received at
least two courses of chemotherapy before entering the
study. Treatment with nitrosoureas ( lomustine [CCNU] and
BCNU) before entry into the study was documented for 23 of
40 (58%) of the patients.
DTI-015 Treatment
The 40 patients received a total of 46 treatments. Thirty -
five patients received one treatment, four received two
treatments, and one received three treatments. Twenty-
seven of the treatments consisted of one injection, 18 of the
treatments consisted of two injections, and 1 treatment
consisted of three injections.
A summary of number of patients, treatments, volume,
and milligram dose of DTI-015 administered at each dose
level is shown in Table 2. The total volumes of DTI-015
administered ranged from 0.44 to 10.5 ml, and the total
doses of BCNU ranged from 7.5 to 369 mg per treatment.
Adverse Events and MTD Determination
Protocol 95-115 called for identification of adverse events
that were both high grade [3, 4, or 5 (severe, life-
threatening, or fatal, respectively) ] and related to investiga-
tional treatment (HGR-AEs). Fifteen of the 46 treatments
(33%) administered to 14 patients resulted in high-grade
events judged related (possibly, probably, or definitely) to
DTI-015 treatment.
The frequency of HGR-AEs increased at both the higher
injection volumes and the higher BCNU milligram doses
administered. The distribution of HGR-AEs as a function of
dose level cohort is shown in Table 3.
The HGR-AEs encountered at 12.5 mg/ml (during the
volume escalation phase of the study) were predominantly
from treatments using volumes above 5 ml (4 of 5), whereas
those encountered during the concentration escalation
phase of the trial are predominantly from treatments using
BCNU dose 240 mg (8 of 10).
The frequency of HGR-AEs as a function of injection
volume for all 40 patients (46 treatments) is shown in Figure
1. Overall, 9 of 35 treatments (26%) using a DTI-015
injection volume of 5 ml resulted in HGR-AEs, compared
to 6/11 treatments (55%) using >5 ml injection volume
yielding a maximally tolerated DTI-015 volume of 5 ml.
Regarding BCNU milligram dose, 7 of 36 treatments
(19%) using <240 mg BCNU resulted in HGR-AEs,
compared to 8 of 10 treatments (80%) using 240 mg
BCNU (Figure 2) yielding a maximally tolerated BCNU dose
of <240 mg.
Taken together, 3 of 28 (11%) DTI-015 treatments using
DTI-015 at 5 ml and <240 mg BCNU resulted in HGR-
AEs compared to 12 of 18 treatments (67%) using DTI-015
at >5 ml or 240 mg BCNU (Table 4). Based upon these
results, the MTD is defined by both volume injected and total
dose administered as 5 ml and 240 mg, respectively.
The 240 mg BCNU treatments resulting in HGR-AEs
were all delivered at 75% tumor volume. In addition to high
absolute milligram dose, they therefore also utilized high
milligram/tumor proportionate dosing of 45 to 56 mg BCNU/
cm3 tumor.
Figure 2. Bar chart showing BCNU dose (mg ) and patient number ordered by increasing milligrams. HGR-AEs are indicated by dark bars.
Table 4. HGR-AEs and DTI -015 Dose.
BCNU dose (mg ) DTI - 015 injection volume
5 ml >5 ml
<240 3 /28 (11%) 4 /8 ( 50%)
240 6 /7 (86%) 2 /3 ( 67%)
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Adverse Events Produced at DTI-015 Doses MTD
The three treatments administered at MTD which
resulted in HGR-AEs produced a total of three events.
Patient 1 exhibited a grade 3 cerebral edema following DTI-
015 injection plus surgical resection and lived 31 weeks
following treatment during which time the edema did not
resolve. Patient 19 presented with severe leg and mild arm
weakness before DTI-015 that progressed to a grade 3
hemiparesis following injection that then resolved and the
patient lived 79 weeks following treatment. Patient 20
presented with a severe and worsening weakness before
DTI-015 that progressed to grade 3 hemiplegia following
injection. This did not resolve before the patient’s expira-
tion 3 weeks following treatment due to unrelated pneumo-
nia. Twenty- five of 28 (89%) DTI-015 treatments at
MTD were administered safely without producing any
HGR-AEs.
Adverse Events Produced at DTI-015 Doses >MTD
The 12 treatments administered at >MTD resulting in
HGR-AEs produced a total of 37 events: patient 10 exhibited
hemiplegia and hematoma; patient 13 exhibited seizure
following a first treatment and then headache, nausea, and
vomiting following a third treatment; patient 25 exhibited
headache, fatigue, and lethargy; patient 28 exhibited hy-
drocephalus, speech impairment, and depressed level of
consciousness; patient 31 exhibited confusion, speech im-
pairment, and right -sided weakness; patient 32 exhibited
right -sided weakness; patient 36 exhibited left hand incoor-
dination and weakness; patient 37 exhibited muscle weak-
ness, speech impairment, cognitive changes, and left
hemiparesis. The milliliter and milligram dose each of these
patients received is shown in Figures 1 and 2.
Three deaths were considered possibly related to DTI-
015 administered at the highest milliliter volume, milligram
per milliliter concentration, and milligrams studied. Patient 14
did not meet protocol eligibility criteria but was treated on a
compassionate basis. He had brain herniation and a KPS of
50 at the time of enrollment. He received the highest injection
volume administered in the study (10.5 ml), experienced
respiratory distress, respiratory failure, hypertension, unre-
sponsiveness, dilated pupils, raised intracranial pressure,
and eventually succumbed because of respiratory failure on
day 3 posttreatment. Patient 39 exhibited ataxia, decreased
level of consciousness, neuropathy, speech impairment,
urinary incontinence, and dehydration following DTI-015
administration (75 mg/ml, 369 mg) and although his
condition improved upon discharge died 7 weeks following
the administration of DTI-015. Patient 40 experienced two
focal seizures immediately following DTI-015 (75 mg/ml,
264 mg), was administered phenobarbital, then experienced
a decreased level of consciousness, decreased respiratory
rate, and hypoxia requiring intubation and ICU care. In
addition, the patient experienced left lower lobe pneumonia,
urinary tract infection, and a candida superinfection and
expired 4 weeks following treatment.
All HGR-AEs were CNS associated and occurred in the
immediate postoperative period. There were none of the
systemic adverse reactions that might be expected from
administration of BCNU, including no episodes of delayed
myelosuppression following treatment with DTI-015 up to
the maximum dose of BCNU administered (369 mg). There
were no reports of adverse changes in any laboratory
parameters.
Survival
As of October 24, 2001 three of the 40 patients are still
alive. The median survival time for the entire population
(n=40) was 31 weeks and 13 weeks for non–GBM patients
(n=14). The median survival of patients with GBM (n=26)
Figure 3. Kaplan Meier survival curve for recurrent inoperable GBM patients
following DTI - 015 [median survival time of 55±15 (SE ) weeks ], compared to
MDACC recurrent GBM historical data [median survival time of 25±5 (SE )
weeks ] which includes operable and inoperable patients.
Figure 4. Post –DTI - 015 MR images (T1 -weighted axial images without
contrast ) demonstrating a combined hyperintense and hypointense signal 24
hours following injection. Patients 27 (A and C), 16 (B ), and 26 (D ).
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was 32 weeks. The median survival of GBM patients treated
with DTI-015 doses MTD (n=16) was 55 weeks, whereas
the median survival of GBM patients treated with doses
>MTD (n=10) was 19 weeks.
Figure 3 shows the Kaplan Meier survival curves for
GBM patients receiving DTI-015 doses MTD compared
to the MDACC historical data for recurrent operable and
inoperable GBM patients (median survival time 25 weeks,
Ref. [15] ).
Magnetic Resonance Imaging
Following intratumoral DTI-015 injection, the signal
detected on T1-weighted MR images acquired in the
absence of contrast medium (Figure 4, A–D ) was typically
hyperintense with hypodense foci, some of which were
confluent spots. This signal was present in all evaluable
patients (n=25) and often lasted for several months.
The size of the signal abnormality and the fact that it
was superimposed upon the tumor images made routine
assessment of tumor shrinkage (complete or partial res-
ponse) impractical in most patients. MRI, however, was
routinely useful in assessing stable disease (an unchanging
T1-weighted contrast enhanced signal ) and progressive
disease (an increasing T1-weighted contrast enhanced
signal ), as demonstrated for patient 6 (Figure 5). Eighteen
of 25 (72%) evaluable patients exhibited stable disease
with a median of 10.5 weeks ( range 4 to 40 weeks) and
13 of these patients were stable at last follow-up (median
8 weeks, range 4 to 16 weeks). Seven of 25 evaluable
patients (28%) progressed at first follow-up with a median of
4 weeks (range 4 to 8 weeks).
Although atypical, tumor volume reduction was seen in
some patients with minimal DTI-015- induced MRI signal
(Figure 6).
Discussion
This phase I / II trial was undertaken to identify a MTD of DTI-
015 and investigate its safety and activity when administered
by stereotactic injection in patients with inoperable malignant
glioma. A dual phase dose escalation was employed and
identified the MTD of DTI-015 in the study population to be 5
ml and 240 mg. When administered at MTD, DTI-015 was
well tolerated, and produced a median survival time of 55
weeks in heavily pretreated patients with inoperable recur-
rent GBM.
Our goal was to establish the MTD by systematically
increasing dosage until unacceptable toxicity was produced.
Not surprisingly, we found that DTI-015 toxicity in humans is
related to both injection volume and milligram dose as
predicted by preclinical studies in normal feline and rat brain
(unpublished results ). When DTI-015 was administered at
Figure 5. Patient 6 presented 7 months following diagnosis with a recurrent
right thalamic glioblastoma multiforme, which had been increasing in size
every 3 weeks following radiation and chemotherapy. All MR images are axial
T1 -weighted images with contrast. Preinjection MRI tumor volume was 8 ml
(A ). Twenty - four hours post –DTI - 015 (B ). Tumor volume decreased to 5.4
ml at 6 months (C ). At 7 months, a contrast enhancing area of new tumor
growth occurred (D, arrows ). A second DTI - 015 injection was performed at 8
months (E ). Twenty - four hours post –second DTI -015 injection, a mixed
hyperintense and hypointense signal is seen (F ). One year post– initial DTI -
015 treatment, areas of contrast enhancement appeared anterior and superior
to the tumor (G ) and inferior in the brainstem (H ) indicating tumor regrowth.
The patient survived 59 weeks from the first DTI - 015 injection.
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>MTD, a high frequency of HGR-AEs resulted (67%, 12 of
18 treatments) with a severity that peaked at the highest
milliliter (10.5), milligram (369), and milligram per milliliter
(75) doses studied.
In sharp contrast, when administered at MTD, DTI-015
was well tolerated resulting in only three HGR-AEs from 28
treatments with 25 of these treatments (89%) being
administered safely. The safety of DTI-015 exhibited in this
trial would seem especially encouraging given the inoperable
nature of the tumors treated.
It is not clear if 240 mg is an absolute dose that should not
be exceeded or if this dose can in fact be exceeded if
administered at less than 75% tumor volume, that is,
administered into tumors larger than those included in this
study. An ongoing multicenter trial evaluating DTI-015 in
inoperable recurrent GBM sized up to 33.4 cm3 should help
answer this question.
The median survival for patients with recurrent inoper-
able GBM of 55 weeks following treatment with DTI-015
at MTD compares favorably with survival results from
other studies. The historical cumulative experience of 225
patients with recurrent GBM enrolled in eight consecutive
phase II chemotherapy studies at MDACC ( including ope-
rable and inoperable patients) was 25 weeks [15]. Recent
studies of temozolomide and procarbazine at first recur-
rence in patients with GBM reported median progression-
free survivals of 9 to 12 weeks and overall survival times of
23 to 29 weeks after chemotherapy was initiated [2,17].
Although proof of efficacy can only be demonstrated in a
randomized prospective clinical trial, the current findings of
a two- fold increase in survival with DTI-015 compared to
these studies of systemic chemotherapy agents are quite
encouraging.
Although the MRI signal changes following injection of
DTI-015 prohibited an assessment of initial tumor shrink-
age in most patients, MRI was valuable in determining
stable disease (an unchanging T1-weighted contrast en-
hanced signal ) and progressive disease (an increasing
T1-weighted contrast enhanced signal ). The incidence of
stable disease achieved in 72% of evaluable patients for
a median of 10.5 weeks suggests DTI-015-produced
anti– tumor activity. The explanation of the DTI-015-
induced MRI signal appearance is unknown. Nonetheless,
over long time periods of 6 to 12 months, the majority of
these MRI signal changes regressed. Although the ap-
parent distribution of DTI-015 shadowed the T1-weighted
tumor image on the MRI scans, there is insufficient data at
this time to correlate this treatment - induced signal with
clinical activity. Diffusion MRI is currently being evaluated
for its potential to map the spatial distribution of DTI-015
anti– tumor activity in gliomas.
In conclusion, the results of this trial have identified a MTD
of DTI-015. When administered at MTD, DTI-015 is well
tolerated and results in a median survival of 55 weeks in
heavily pretreated patients with inoperable recurrent GBM.
Based on these findings, a randomized prospective clinical
trial of DTI-015 is planned to definitively evaluate its efficacy
in patients with GBM.
Figure 6. Patient 29 presented 7 months following diagnosis with a recurrent
posterior frontal lobe glioblastoma multiforme following two resections,
chemotherapy, and radiation. All MR images are coronal T1 weighted with
contrast. Preinjection tumor volume was 3.7 ml (A ). Twenty - four hours post –
DTI - 015 demonstrates a predominantly hypointense signal intensity and
decreased contrast enhancement (B ). The tumor demonstrated a small ring
lesion with central hypointensity at 1–4 months (C–F ) and then a slight
increase in enhancement at 5 months (G ). Six months postinjection (H ), the
area inferior to the injection progressed as demonstrated by increasing
contrast enhancement. At 8 months post –DTI -015 injection, this region and
the injected area were resected. The resected region injected with DTI - 015
had a ‘‘hard rock’’ consistency. Histological examination of this region
demonstrated necrosis, with microscopic foci of tumor at the edges (although
no tumor growth ). A biopsy of the wall of a previous resection cavity
demonstrated tumor mass and diffuse infiltrating tumor.
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